68Ga and 18F quantification, and detectability of hot spots using an ACR Phantom: contributions of radionuclide physical differences to hot spot detectability

M Silosky, R Karki, B Chin - 2019 - Soc Nuclear Med
1200 Introduction: 68 Ga DOTATATE is currently the standard of care for PET imaging for
suspected neuroendocrine tumors. The 68 Ga radiometal is easily chelated, and is a …

[HTML][HTML] Physical characteristics of 68Ga DOTATATE PET/CT affecting small lesion detectability

MS Silosky, R Karki, R Morgan… - American journal of …, 2021 - ncbi.nlm.nih.gov
Background and purpose: 68 Ga DOTATATE PET/CT protocols are similar to 18 F FDG
protocols despite differences in physical properties, biodistribution, and tumor uptake. The …

68Ga DOTATATE organ specific tumor signal to noise (S/N) ratios: comparison of lesion detectability from phantom studies to lesion detectability in clinical practice

B Chin, M Silosky, R Morgan, R Karki, J Anderson - 2019 - Soc Nuclear Med
478 Introduction: Early detection of metastatic neuroendocrine disease with 68 Ga
DOTATATE PET/CT requires high spatial resolution imaging of small lesions, high tumor …

Normal biodistribution and tumor uptake of 68Ga DOTATATE PET/CT in the clinical setting: normal background activity, and organ specific tumor characterization of …

J Anderson, M Silosky, R Karki, R Morgan, B Chin - 2019 - Soc Nuclear Med
3031 Introduction: 68 Ga DOTATATE PET/CT has demonstrated higher sensitivity and lesion
detectability compared to 111 In octreoscan for suspected neuroendocrine tumors. 68 Ga …

ACR practice parameter for the performance of gallium-68 DOTATATE PET/CT for neuroendocrine tumors

RM Subramaniam, ML Bradshaw, K Lewis… - Clinical nuclear …, 2018 - journals.lww.com
Radiopharmaceuticals targeting cell surface expression of somatostatin receptors (SSTRs)
are particularly useful in the evaluation of neuroendocrine tumors. Gallium-68 DOTA-Tyr 3 …

[HTML][HTML] Efficacy and limitations of 68-gallium DOTATATE PET/CT for neuroendocrine tumors: clinical experience following FDA approval

RW Griffith, E McDonald, L Emmonds, J Gerhold… - HPB, 2018 - hpbonline.org
Background: 68-Gallium DOTATATE PET/CT (GaTate) was approved by the US FDA in
2016 for imaging neuroendocrine tumors (NET). The purpose of this study is to present the …

Target activity repeatability in a clinically relevant phantom: 18F vs 68Ga

M Silosky, L Patten, B Chin - 2021 - Soc Nuclear Med
1442 Objectives: Quantification of tumor uptake in PET imaging is commonly used to
evaluate therapy response. For 18 F FDG PET scans, a threshold of approximately 25% for …

< New kid on the block: A pictorial review of 68Ga-DOTATATE PET/CT imaging advantages, characteristics and potential pitfalls in the evaluation of neuroendocrine …

A Romesberg, ME Oates, R El Khouli - 2017 - Soc Nuclear Med
992 Objectives: 1. Review the physiological bio-distribution patterns of 68 Ga-DOTATATE. 2.
Discuss the role of 68 Ga-DOTATATE in the evaluation, staging, and surveillance of …

A basic study on lesion detectability for hot spot imaging of positron emitters with dedicated PET and positron coincidence gamma camera

H Zhang, T Inoue, M Tian, S Alyafei, N Oriuchi… - Annals of nuclear …, 2001 - Springer
The aim of this study was to explore the correlations of detectability and the semi-
quantification for hot spot imaging with positron emitters in positron emission tomography …

Improved quantification for local regions of interest in preclinical PET imaging

J Cal-González, SC Moore, MA Park… - Physics in Medicine …, 2015 - iopscience.iop.org
Abstract In Positron Emission Tomography, there are several causes of quantitative
inaccuracy, such as partial volume or spillover effects. The impact of these effects is greater …